Suppr超能文献

[儿童原发性甲状腺功能减退继发垂体增生:8例报告]

[Pituitary hyperplasia secondary to primary hypothyroidism in children: report of 8 cases].

作者信息

Xu Ai-Jing, Li Tang

机构信息

Department of Pediatrics, Qingdao University, Qingdao 266003, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jan;12(1):17-20.

Abstract

OBJECTIVE

To study the changes in hormone levels and the therapy of pituitary hyperplasia secondary to primary hypothyroidism in children.

METHODS

The clinical data of 8 children with pituitary hyperplasia secondary to primary hypothyroidism (5 girls and 3 boys) at ages of 5 to 9 years were studied retrospectively. All of the children had a short stature. They were followed up 1 to 6 years.

RESULTS

The thyroid hormone levels decreased and the serum thyroid stimulating hormone (TSH) and prolactin (PRL) levels increased in the 8 children. After 2 to 6 months thyroxine replacement therapy, the levels of free triiodothyronine (FT3), free thyroxine (FT4) and serum TSH and PRL returned to normal, and the pituitary enlargement regressed to normal in the 8 children. Of them, 6 children's height growth rate increased significantly from 3.1+/-0.5 cm per year to 11.6+/-1.7 cm per year (p<0.01). The other 2 cases had low growth rate and then received additional recombinant human growth hormone (rhGH) therapy. Their height growth rate increased by 11 cm per year. Pituitary hyperplasia did not recur in the 8 children during the follow-up.

CONCLUSIONS

The thyroid function and pituitary examinations are necessary for children with a short stature. Thyroxine substitution therapy appears to be effective for primary hypothyroidism secondary to pituitary hyperplasia. rhGH replacement therapy after regression of the pituitary enlargement can result in a satisfactory height growth in children with low thyroid hormone levels and growth hormone deficiency.

摘要

目的

研究儿童原发性甲状腺功能减退继发垂体增生时激素水平的变化及治疗方法。

方法

回顾性分析8例年龄5至9岁的原发性甲状腺功能减退继发垂体增生患儿(5例女孩,3例男孩)的临床资料。所有患儿均身材矮小。随访1至6年。

结果

8例患儿甲状腺激素水平降低,血清促甲状腺激素(TSH)和催乳素(PRL)水平升高。经2至6个月的甲状腺素替代治疗后,8例患儿的游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平及血清TSH和PRL恢复正常,垂体增大消退至正常。其中6例患儿身高生长速率从每年3.1±0.5厘米显著增至每年11.6±1.7厘米(p<0.01)。另外2例生长速率较低,随后接受了重组人生长激素(rhGH)补充治疗,其身高生长速率每年增加11厘米。8例患儿随访期间垂体增生未复发。

结论

身材矮小的儿童有必要进行甲状腺功能及垂体检查。甲状腺素替代治疗对原发性甲状腺功能减退继发垂体增生似乎有效。垂体增大消退后进行rhGH补充治疗可使甲状腺激素水平低且生长激素缺乏的患儿身高获得满意增长。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验